• / Free eNewsletters & Magazine
  • / My Account
Home>Mylan Rejects Teva's Unsolicited $40 Billion Bid--2nd Update

Mylan Rejects Teva's Unsolicited $40 Billion Bid--2nd Update

3party Content

Mon, 27 Apr 2015

By Tess Stynes Mylan NV on Monday said its board unanimously rejected the unsolicited bid from Teva Pharmaceutical Industries Ltd., the latest move in a three-way tussle as the generic-drug industry faces challenges from slowing growth. Robert J. Coury, Mylan's executive chairman, said Teva's
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.